At the end of phase 2, the firm will reach a crossroad—it could join forces with other investors to fund phase 3 studies, or set its spinouts up to go public, he added.
And Aditum isn’t just pushing drugs through the clinic. It’s also pairing each drug it makes with a digital tool to help patients get the most out of their medicine.
“We believe in these large patient population disease areas that behavior modification is just as important as getting the therapy we’re going to be providing,” Jimenez said.
The digital tools will most likely be mobile apps, which could, in the case of TMP-301, help patients stick to their treatment plan.
With its current fund closed, Aditum is focusing on finding new programs for more spinouts. But once it’s deployed the $135 million, it will go out and raise a second fund, and then a third, Jimenez said.
“This is a trend that is not going to end soon. There are more therapies available than clinical trial budgets will accommodate, so we think of this as a multiyear, multifund activity,” he said.
・・・